Madrigal Pharmaceuticals has secured worldwide rights to develop ARO-PNPLA3, an experimental treatment created by Arrowhead Pharmaceuticals for people with metabolic dysfunction-associated steatohepatitis (MASH),…
Featured Articles
Latest news & perspectives
Children with biliary atresia who had evidence of active cytomegalovirus (CMV) infection involving bile duct cells in the liver had signs of more severe…
May is Hepatitis Awareness Month, and advocates are working to spread the word about viral hepatitis — a group of infections that cause liver…
